Emerald Clinical Trials Acquires Hongyi Clinical Development Services
Emerald Clinical Trials has acquired Hongyi Clinical Development Services, the independent China-based clinical CRO carved out of WuXi AppTec, creating a uniquely positioned global clinical development platform.
The combination unites Emerald’s global scientific leadership and multi-regional delivery with Hongyi’s operational scale, strong site relationships in China, global regulatory depth, and deep biometrics and statistics expertise: one integrated partner, 1,000+ professionals across 40+ countries and 70+ locations, supporting sponsors from first-in-human through post-marketing across China, Asia-Pacific, Europe, and the Americas.
Emerald Clinical Trials remains our single global master brand, and our brand outside China is unchanged. In China, our operations now carry the name Emerald Clinical 弘翼临床, combining the Emerald global signature with the trusted Hongyi name.
Emerald Clinical’s brand in the US, EU and APAC remain unchanged:
What this means for our clients
- Combined scientific leadership. Deep therapy-area expertise and global KOL networks, now strengthened by proven delivery capability in China.
- An end-to-end development pathway. Early-phase and first-in-human capabilities across Australia and China, transitioning seamlessly into multi-regional later-phase development and registration.
- One integrated team. Same trusted teams, unified global networks, consistent quality standards worldwide.
About Emerald Clinical Trials
Emerald Clinical Trials is a global, full-service CRO with over 25 years of experience, partnering with 160+ biotechnology companies and 15 of the world’s top 20 pharmaceutical firms. Headquartered in Singapore, with 1,000+ professionals across 40+ countries and a collaborative network spanning 70+ locations, Emerald delivers end-to-end Phase I–IV and real-world solutions, with recognized scientific leadership across Renal, Oncology, Cardiometabolic, Autoimmune, Ophthalmology, and Early Phase development. For more information, visit www.emeraldclinical.com.
About Hongyi Clinical Development Services
Hongyi Clinical Development Services is a leading China-based clinical CRO, formerly the independent clinical development business of WuXi AppTec. Hongyi provides comprehensive solutions from early development through post-marketing studies for global sponsors, combining deep therapeutic, biometrics, and statistical expertise, advanced technology, and operational excellence to accelerate clinical development and bring innovative therapies to patients.
If you have any questions, please reach out to your Emerald representative or email us at ecmarketing@emeraldclinical.com.